Eurobio Scientific SA (ALERS) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.030x

Based on the latest financial reports, Eurobio Scientific SA (ALERS) has a cash flow conversion efficiency ratio of 0.030x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€5.36 Million ≈ $6.26 Million USD) by net assets (€180.85 Million ≈ $211.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Eurobio Scientific SA - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Eurobio Scientific SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Eurobio Scientific SA total liabilities for a breakdown of total debt and financial obligations.

Eurobio Scientific SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Eurobio Scientific SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Honghua Group Limited
F:4HB
0.011x
JEIO CO LTD (PROPOSED)
KQ:418550
0.000x
Bank Yudha Bhakti Tbk
JK:BBYB
0.020x
Praemium Ltd
AU:PPS
0.056x
Activate Energy Acquisition Corp. Class A Ordinary Share
NASDAQ:AEAQ
24.834x
First National Corp
NASDAQ:FXNC
0.045x
Hyundai Cement
KO:006390
0.059x
Secuoya Grupo de Comunicación S.A
MC:SEC
0.018x

Annual Cash Flow Conversion Efficiency for Eurobio Scientific SA (2007–2024)

The table below shows the annual cash flow conversion efficiency of Eurobio Scientific SA from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see ALERS stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €178.85 Million
≈ $209.10 Million
€16.70 Million
≈ $19.53 Million
0.093x -38.88%
2023-12-31 €175.17 Million
≈ $204.80 Million
€26.77 Million
≈ $31.29 Million
0.153x -38.74%
2022-12-31 €172.67 Million
≈ $201.87 Million
€43.07 Million
≈ $50.36 Million
0.249x -39.36%
2021-12-31 €160.22 Million
≈ $187.32 Million
€65.92 Million
≈ $77.06 Million
0.411x -19.23%
2020-12-31 €107.84 Million
≈ $126.08 Million
€54.93 Million
≈ $64.22 Million
0.509x +273.22%
2019-12-31 €36.56 Million
≈ $42.75 Million
€4.99 Million
≈ $5.83 Million
0.136x +872.96%
2018-12-31 €29.62 Million
≈ $34.63 Million
€-523.00K
≈ $-611.44K
-0.018x -122.61%
2017-12-31 €31.69 Million
≈ $37.05 Million
€2.48 Million
≈ $2.89 Million
0.078x +128.78%
2016-12-31 €12.23 Million
≈ $14.29 Million
€-3.32 Million
≈ $-3.88 Million
-0.271x -158.84%
2015-12-31 €23.31 Million
≈ $27.25 Million
€-2.44 Million
≈ $-2.86 Million
-0.105x +13.43%
2014-12-31 €27.95 Million
≈ $32.67 Million
€-3.38 Million
≈ $-3.96 Million
-0.121x +49.18%
2013-12-31 €20.56 Million
≈ $24.04 Million
€-4.90 Million
≈ $-5.73 Million
-0.238x -31.31%
2012-12-31 €24.50 Million
≈ $28.64 Million
€-4.45 Million
≈ $-5.20 Million
-0.182x +59.12%
2011-12-31 €13.57 Million
≈ $15.86 Million
€-6.02 Million
≈ $-7.04 Million
-0.444x -46.82%
2010-12-31 €19.19 Million
≈ $22.44 Million
€-5.80 Million
≈ $-6.78 Million
-0.302x -14.79%
2009-12-31 €25.46 Million
≈ $29.76 Million
€-6.71 Million
≈ $-7.84 Million
-0.263x +73.33%
2008-12-31 €9.74 Million
≈ $11.39 Million
€-9.62 Million
≈ $-11.24 Million
-0.988x -261.60%
2007-12-31 €18.07 Million
≈ $21.12 Million
€-4.93 Million
≈ $-5.77 Million
-0.273x --

About Eurobio Scientific SA

PA:ALERS France Medical Devices
Market Cap
$264.84 Million
€226.54 Million EUR
Market Cap Rank
#15926 Global
#234 in France
Share Price
€22.50
Change (1 day)
-1.75%
52-Week Range
€20.60 - €25.70
All Time High
€28.88
About

Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more